BridgeBio Pharma Statistics
Total Valuation
BBIO has a market cap or net worth of $4.60 billion. The enterprise value is $5.89 billion.
| Market Cap | 4.60B |
| Enterprise Value | 5.89B |
Important Dates
The next estimated earnings date is Thursday, May 2, 2024, before market open.
| Earnings Date | May 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BBIO has 184.45 million shares outstanding. The number of shares has increased by 10.39% in one year.
| Shares Outstanding | 184.45M |
| Shares Change (YoY) | +10.39% |
| Shares Change (QoQ) | +6.85% |
| Owned by Insiders (%) | 5.37% |
| Owned by Institutions (%) | 92.15% |
| Float | 113.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 494.69 |
| Forward PS | 39.15 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 633.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.32
| Current Ratio | 3.32 |
| Quick Ratio | 3.15 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.91 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -110.40% |
| Return on Capital (ROIC) | -157.52% |
| Revenue Per Employee | $16,915 |
| Profits Per Employee | -$1.17M |
| Employee Count | 550 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +64.69% in the last 52 weeks. The beta is 1.03, so BBIO's price volatility has been similar to the market average.
| Beta (1Y) | 1.03 |
| 52-Week Price Change | +64.69% |
| 50-Day Moving Average | 30.69 |
| 200-Day Moving Average | 30.61 |
| Relative Strength Index (RSI) | 30.56 |
| Average Volume (30 Days) | 1,700,812 |
Short Selling Information
The latest short interest is 14.28 million, so 7.74% of the outstanding shares have been sold short.
| Short Interest | 14.28M |
| Short Previous Month | 13.41M |
| Short % of Shares Out | 7.74% |
| Short % of Float | 12.64% |
| Short Ratio (days to cover) | 7.45 |
Income Statement
In the last 12 months, BBIO had revenue of $9.30 million and -$643.20 million in losses. Loss per share was -$3.95.
| Revenue | 9.30M |
| Gross Profit | 6.86M |
| Operating Income | -607.37M |
| Pretax Income | -643.20M |
| Net Income | -643.20M |
| EBITDA | -551.39M |
| EBIT | -561.91M |
| Loss Per Share | -$3.95 |
Balance Sheet
The company has $451.54 million in cash and $1.74 billion in debt, giving a net cash position of -$1.29 billion or -$6.98 per share.
| Cash & Cash Equivalents | 451.54M |
| Total Debt | 1.74B |
| Net Cash | -1.29B |
| Net Cash Per Share | -$6.98 |
| Equity / Book Value | -1.35B |
| Book Value Per Share | -7.34 |
| Working Capital | 333.75M |
Cash Flow
In the last 12 months, operating cash flow was -$527.72 million and capital expenditures -$1.31 million, giving a free cash flow of -$529.03 million.
| Operating Cash Flow | -527.72M |
| Capital Expenditures | -1.31M |
| Free Cash Flow | -529.03M |
| FCF Per Share | -$3.25 |
Margins
Gross margin is 73.71%, with operating and profit margins of -6,528.75% and -6,913.92%.
| Gross Margin | 73.71% |
| Operating Margin | -6,528.75% |
| Pretax Margin | -6,913.92% |
| Profit Margin | -6,913.92% |
| EBITDA Margin | -5,926.98% |
| EBIT Margin | -6,040.13% |
| FCF Margin | -5,686.62% |
Dividends & Yields
BBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.39% |
| Shareholder Yield | -10.39% |
| Earnings Yield | -13.98% |
| FCF Yield | -11.50% |
Analyst Forecast
The average price target for BBIO is $47.44, which is 90.14% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $47.44 |
| Price Target Difference | 90.14% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 197.91% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BBIO has an Altman Z-Score of -7.74 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.74 |
| Piotroski F-Score | 1 |